Sign inJoin free

Watch / Small Cap

BCAL's key breast cancer test milestone

13 Dec 20247:21

BCAL's key breast cancer test milestone

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Jayne Shaw from BCAL Diagnostics (ASX: BDX) discusses the accreditation of their North Ryde Laboratory, calling it a significant milestone for commercialising their breast cancer blood test. Scheduled for a soft launch in Sydney by early 2025, this test aims to complement traditional mammographies.

BCAL Diagnostics (ASX: BDX) successfully raised $10 million in August, with plans to expand nationally and internationally, including the US. Jayne mentions ongoing collaborations with labs in North Carolina, Chicago, and Minneapolis to ensure a smooth rollout of the test in various markets.

The test offers a non-invasive alternative to mammography, especially benefiting women under 40. With an initial cost of $300, Jayne emphasises the potential of the test to stand alone eventually and highlights the company's commitment to making breast cancer detection more accessible.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy